A Retrospective Analysis of Outcomes Amongst COVID-19 Infected Patients with Acute Hepatitis Receiving N-Acetylcysteine Therapy in a Safety Net Hospital

Pellegrini et al., Gastroenterology, doi:10.1016/S0016-5085(21)02756-6, May 2021

N-acetylcysteine for COVID-19

14th treatment shown to reduce risk in February 2021, now with p = 0.000002 from 26 studies, recognized in 3 countries.

No treatment is 100% effective.
Protocols combine treatments.

Retrospective 864 hospitalized late stage COVID-19 patients in the USA, 138 receiving NAC treatment for acute hepatitis, showing lower mortality with treatment. Results are adjusted for confounders, however details are not provided.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
OutcomeImprovementEffect · pTreatmentControl
risk of death 51.7% lower · OR 0.48 · p < 0.001*** 51.7% lowerOR 0.48p < 0.001*** 138 726 treatment 138, control 726adjusted per studyinverted to make OR<1 favor treatmentRR approximated with ORmultivariable

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. *** p < 0.001

Pellegrini et al., 23 May 2021, retrospective, USA, peer-reviewed, 10 authors, study period March 2020 - May 2020.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Abstract: Powered by TCPDF (www.tcpdf.org)
DOI record: { "DOI": "10.1016/s0016-5085(21)02756-6", "ISSN": [ "0016-5085" ], "URL": "http://dx.doi.org/10.1016/s0016-5085(21)02756-6", "alternative-id": [ "S0016508521027566" ], "author": [ { "affiliation": [], "family": "Pellegrini", "given": "James R.", "sequence": "first" }, { "affiliation": [], "family": "Munshi", "given": "Rezwan F.", "sequence": "additional" }, { "affiliation": [], "family": "Russe-Russe", "given": "Jose R.", "sequence": "additional" }, { "affiliation": [], "family": "Berman", "given": "Lorin", "sequence": "additional" }, { "affiliation": [], "family": "George", "given": "Reshma", "sequence": "additional" }, { "affiliation": [], "family": "Veeramani", "given": "Swarna", "sequence": "additional" }, { "affiliation": [], "family": "Kagolanu", "given": "Deepthi", "sequence": "additional" }, { "affiliation": [], "family": "Srivastava", "given": "Pranay", "sequence": "additional" }, { "affiliation": [], "family": "Rizvon", "given": "Kaleem", "sequence": "additional" }, { "affiliation": [], "family": "Mustacchia", "given": "Paul", "sequence": "additional" } ], "container-title": [ "Gastroenterology" ], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 5, 10 ] ], "date-time": "2021-05-10T15:20:22Z", "timestamp": 1620660022000 }, "deposited": { "date-parts": [ [ 2021, 9, 24 ] ], "date-time": "2021-09-24T13:40:27Z", "timestamp": 1632490827000 }, "indexed": { "date-parts": [ [ 2021, 12, 9 ] ], "date-time": "2021-12-09T07:29:59Z", "timestamp": 1639034999386 }, "is-referenced-by-count": 0, "issn-type": [ { "type": "print", "value": "0016-5085" } ], "issue": "6", "issued": { "date-parts": [ [ 2021, 5 ] ] }, "journal-issue": { "issue": "6", "published-print": { "date-parts": [ [ 2021, 5 ] ] } }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 5, 1 ] ], "date-time": "2021-05-01T00:00:00Z", "timestamp": 1619827200000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0016508521027566?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0016508521027566?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "S-848", "prefix": "10.1016", "published": { "date-parts": [ [ 2021, 5 ] ] }, "published-print": { "date-parts": [ [ 2021, 5 ] ] }, "publisher": "Elsevier BV", "reference-count": 0, "references-count": 0, "relation": {}, "score": 1, "short-container-title": [ "Gastroenterology" ], "short-title": [], "source": "Crossref", "subject": [ "Gastroenterology", "Hepatology" ], "subtitle": [], "title": [ "Su320 A RETROSPECTIVE ANALYSIS OF OUTCOMES AMONGST COVID-19 PATIENTS WITH ACUTE HEPATITIS RECEIVING N-ACETYLCYSTEINE THERAPY IN A SAFETY NET HOSPITAL" ], "type": "journal-article", "volume": "160" }
Late treatment
is less effective